Physician profile
Bibi Koo
NPI 1083857809
$3,872.28
in general payments reported to CMS, 2019-2025
21 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $592 · 2024: $2,021 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $687.96 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $324.97 | 2023-2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $324.71 | 2024-2025 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $235.43 | 2024-2025 | |
| Abbott Laboratories | $233.33 | 2024 | Cardiomems, Mitraclip |
| Corcept Therapeutics | $213.63 | 2024-2025 | Korlym |
| Abiomed | $209.89 | 2024 | Impella |
| Insmed, INC. | $194.12 | 2024-2025 | Arikayce |
| Dexcom, INC. | $149.96 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Cvrx, INC. | $137.79 | 2025 | Barostim Neo System |
| Neurocrine Biosciences, INC. | $124.95 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $124.95 | 2024 | Rexulti |
| Axonics, INC. | $118.06 | 2024 | Axonics, Bulkamid |
| Amgen INC. | $115.22 | 2025 | |
| Genzyme Corporation | $105.36 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $103.22 | 2023 | Quviviq |
| Novo Nordisk INC | $102.21 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.18 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $94.96 | 2024 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $85.43 | 2024 | |
| Sanofi Pasteur INC. | $84.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bibi Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.